These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 17989103)

  • 1. Mycophenolate mofetil or standard therapy for membranous nephropathy and focal segmental glomerulosclerosis: a pilot study.
    Senthil Nayagam L; Ganguli A; Rathi M; Kohli HS; Gupta KL; Joshi K; Sakhuja V; Jha V
    Nephrol Dial Transplant; 2008 Jun; 23(6):1926-30. PubMed ID: 17989103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequential maintenance therapy with cyclosporin A and mycophenolate mofetil for sustained remission of childhood steroid-resistant nephrotic syndrome.
    Gellermann J; Ehrich JH; Querfeld U
    Nephrol Dial Transplant; 2012 May; 27(5):1970-8. PubMed ID: 21976740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective controlled study on mycophenolate mofetil and prednisolone in the treatment of membranous nephropathy with nephrotic syndrome.
    Chan TM; Lin AW; Tang SC; Qian JQ; Lam MF; Ho YW; Tse KC; Chan KW; Lai KN; Tang CS
    Nephrology (Carlton); 2007 Dec; 12(6):576-81. PubMed ID: 17995584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mycophenolate mofetil and prednisolone therapy in children with steroid-dependent nephrotic syndrome.
    Bagga A; Hari P; Moudgil A; Jordan SC
    Am J Kidney Dis; 2003 Dec; 42(6):1114-20. PubMed ID: 14655181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mycophenolate mofetil treatment for primary glomerular diseases.
    Choi MJ; Eustace JA; Gimenez LF; Atta MG; Scheel PJ; Sothinathan R; Briggs WA
    Kidney Int; 2002 Mar; 61(3):1098-114. PubMed ID: 11849465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of immunosuppressive agents in treatment of steroid-resistant minimal change disease and primary focal segmental glomerulosclerosis.
    El-Reshaid K; El-Reshaid W; Madda J
    Ren Fail; 2005; 27(5):523-30. PubMed ID: 16152989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mycophenolate mofetil in idiopathic membranous nephropathy: a clinical trial with comparison to a historic control group treated with cyclophosphamide.
    Branten AJ; du Buf-Vereijken PW; Vervloet M; Wetzels JF
    Am J Kidney Dis; 2007 Aug; 50(2):248-56. PubMed ID: 17660026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of primary nephrotic syndrome in elderly Japanese: retrospective analysis of the Japan Renal Biopsy Registry (J-RBR).
    Yokoyama H; Sugiyama H; Narita I; Saito T; Yamagata K; Nishio S; Fujimoto S; Mori N; Yuzawa Y; Okuda S; Maruyama S; Sato H; Ueda Y; Makino H; Matsuo S
    Clin Exp Nephrol; 2015 Jun; 19(3):496-505. PubMed ID: 25230687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of combined cyclosporin A and mycophenolate mofetil therapy in patients with cyclosporin-resistant focal segmental glomerulosclerosis.
    Segarra Medrano A; Vila Presas J; Pou Clavé L; Majó Masferrer J; Camps Doménech J
    Nefrologia; 2011; 31(3):286-91. PubMed ID: 21468162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mycophenolate mofetil treatment in primary glomerular disease: one-year follow-up in steroid dependent and resistant nephrotic syndrome.
    Tasanarong A; Thitiarchakul S
    J Med Assoc Thai; 2006 Aug; 89 Suppl 2():S218-27. PubMed ID: 17044475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mycophenolate mofetil treatment for therapy-resistant glomerulopathies.
    Sahin GM; Sahin S; Kantarci G; Ergin H
    Nephrology (Carlton); 2007 Jun; 12(3):285-8. PubMed ID: 17498124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aggressive treatment may be needed for idiopathic membranous nephropathy with focal segmental glomerulosclerosis lesions.
    Cheng P; Xie Q; Liu S; Liu X; Wang L; Hao CM
    Rev Assoc Med Bras (1992); 2024; 70(4):e20230871. PubMed ID: 38716932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis.
    Chan TM; Tse KC; Tang CS; Mok MY; Li FK;
    J Am Soc Nephrol; 2005 Apr; 16(4):1076-84. PubMed ID: 15728784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tacrolimus therapy in adults with steroid- and cyclophosphamide-resistant nephrotic syndrome and normal or mildly reduced GFR.
    Li X; Li H; Ye H; Li Q; He X; Zhang X; Chen Y; Han F; He Q; Wang H; Chen J
    Am J Kidney Dis; 2009 Jul; 54(1):51-8. PubMed ID: 19406543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mycophenolate Mofetil with Steroid, a Reasonable Alternative to Current First-line Therapy, for Idiopathic Membranous Nephropathy in Resource-constrained Settings: A Randomized, Open-label Study.
    Sharma M; Roy A; Doley PK; Pegu G
    J Assoc Physicians India; 2024 Jun; 72(6):15-19. PubMed ID: 38881128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Mycophenolate mofetil in the treatment of primary nephrotic syndrome].
    Zhao M; Chen X; Chen Y; Liu Z; Liu Y; Lu F; Zhang Y; Wang H
    Zhonghua Yi Xue Za Zhi; 2001 May; 81(9):528-31. PubMed ID: 11809115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Steroid resistant focal segmental glomerulosclerosis: effect of arterial hyalinosis on outcome: single center study.
    Soliman AR; Maamoun H; Soliman H; Ahmed RM
    Rom J Intern Med; 2021 Jun; 59(2):127-133. PubMed ID: 33565308
    [No Abstract]   [Full Text] [Related]  

  • 18. Use of mycophenolate mofetil in resistant membranous nephropathy.
    Miller G; Zimmerman R; Radhakrishnan J; Appel G
    Am J Kidney Dis; 2000 Aug; 36(2):250-6. PubMed ID: 10922302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment with mycophenolate mofetil and prednisolone for steroid-dependent nephrotic syndrome.
    Afzal K; Bagga A; Menon S; Hari P; Jordan SC
    Pediatr Nephrol; 2007 Dec; 22(12):2059-65. PubMed ID: 17938973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mycophenolate mofetil monotherapy in membranous nephropathy: a 1-year randomized controlled trial.
    Dussol B; Morange S; Burtey S; Indreies M; Cassuto E; Mourad G; Villar E; Pouteil-Noble C; Karaaslan H; Sichez H; Lasseur C; Delmas Y; Nogier MB; Fathallah M; Loundou A; Mayor V; Berland Y
    Am J Kidney Dis; 2008 Oct; 52(4):699-705. PubMed ID: 18585835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.